Vol. 5, No. 11, p. 641-646 - Dec. 31, 2018
The pros and cons pertaining to tuberculosis and tuberculosis protocols
There are many pros and cons with the protocols used to diagnose patient with TB, particularly because research isn't able to correlate findings with the virulence of the tuberculosis pathogen. This has resulted in further experiments to try optimise protocols for better evaluation of susceptible and resistant tuberculosis strains. This indicates the need for more health-care facilities to treat patients with tuberculosis, or co-tuberculosis infections, more precisely. This article presents some advantages and disadvantages of tuberculosis treatment protocols, with emphasis on drugs, tuberculosis data sets and the administration of plant compounds. This paper also highlights some points on the mechanism of drug action with tuberculosis. Controversies and the present status of tuberculosis studies are also commented on. This is the first (generalised) paper to highlight laboratory as well as non-laboratory points pertaining to tuberculosis and tuberculosis protocols.
Mycobacterium tuberculosis; Antimicrobials; Inhibitory; Stimulatory; Immunosuppression; Virulent; Immunocompromised; Pathogenesis; Cytology; Susceptibility; Resistance.
Alexander, S. K.; Strete, D. Microbiology: A photographic atlas for the laboratory. USA: Benjamin Cummings, Addison Wesley Longman Inc., 2001.
Humphries, R. M.; Hindler, J. A. Emerging resistance: new antimicrobial agents - but no test! The challenge of antimicrobial susceptibility in the current US respiratory landscape. Clinical Infectious Diseases, v. 63, no. 1, p. 83-86, 2016. https://doi.org/10.1093/cid/ciw201
James, H.; Jorgensen, J. Antimicrobial susceptibility testing: A review of general principles. Clinical Infectious Disease, v. 49, no. 11, p. 1749-1755, 2009. https://doi.org/10.1086/647952
Jenkins, S.; Jerris, R. Critical assessment of issues applicable to development of antimicrobial susceptibility testing breakpoints. Journal of General Microbiology, v. 10, p. 49-55, 2011. https://doi.org/10.1128/JCM.00837-11
Petrini, B.; Hoffner, S. Drug-resistant and multidrug resistant tubercle bacilli. International Journal of Antimicrobial Agents, v. 13, p. 93-97, 1999. https://doi.org/10.1016/S0924-8579(99)00111-9
Singh, R. Minimum inhibitory concentrations: Interpretation and cross-sectional analysis in an unstandardized 7H9 Mycobacterium tuberculosis broth-based system: A hypothetical case. Journal of Pure and Applied Microbiology, v. 7, no. 1, p. 777-784, 2013.
Singh, R. Mycobacterium tuberculosis: Telling a story of truths. Journal of Pure and Applied Microbiology, v. 5, no. 1, p. 541-544, 2011.
Singh, R. personal writing. Representing the Republic of South Africa, my country, 2018.
Starr, R.; Taggart, R. Biology: The unity and diversity of life. 9. ed. Brooks/Cole Publication, 2001.
Victor, T. C.; Warren, R.; Butt, J. L.; Jordaan, A. M.; Felix, J. V.; Venter, A.; Sirgel, F. A.; Schaaf H. S; Donald, P. R.; Richardson, M.; Cynamon, M. H.; van Helder, P. D. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. Journal of Medical Microbiology, v. 46, p. 847-857, 1997. https://doi.org/10.1099/00222615-46-10-847
Wolinsky E. Statement of the tuberculosis committee. Infectious Disease Society of America, v. 16, p. 627-626, 1993.